High-Level Overview
Statacor Biosciences LLC is a small biotechnology and research & development company based in Rockville, Maryland, operating in the pharmaceuticals, healthcare, and biotech sectors.[1][3][4] Founded around 2010, it employs 1-19 people and generates estimated annual revenue between $131,000 and $5 million, focusing on R&D activities potentially related to home health care services or biosciences innovation.[1][3][4][5] Limited public details suggest it serves niche needs in biotech R&D, but specific products, clients, or growth metrics remain undisclosed in available sources, indicating a low-profile operation with modest scale.[1][6]
Origin Story
Statacor Biosciences was founded in 2010 by Suki Shah amid the 2008-2009 financial crisis, a challenging period exemplified by the Lehman Brothers collapse.[4][7] Incorporated in Maryland and located at addresses like 133 or 10854 Rollins Ave in Rockville, the company emerged during economic turmoil, with Shah starting it "around the time you don't want to start a company."[4][5][7] Little is documented about Shah's background, the idea's emergence, or early traction, but its persistence through over a decade points to resilience in a tough funding environment for biotech startups.[3][7]
Core Differentiators
Public information on Statacor Biosciences is sparse, limiting insights into unique strengths, but available data highlights:
- Small, agile operation: 1-19 employees enable low overhead and flexibility, similar to efficient CRO models emphasizing cost reduction and quick response.[1][5]
- Biotech R&D focus: Operates in research & development within biotechnology, pharmaceuticals, and healthcare, potentially differentiating through specialized, hands-on expertise despite modest revenue ($131K-$5M).[1][3][4]
- Rockville location: Proximity to Maryland's biotech hub (e.g., near NIH and major pharma) provides access to talent and networks, though no track record of major deals or products is noted.[3][4][5]
- Longevity in adversity: Survived founding during financial crisis, suggesting operational resilience over flashy innovation.[7]
No details on products, developer tools, pricing, or community emerge, distinguishing it mainly by endurance rather than publicized breakthroughs.[1][6]
Role in the Broader Tech Landscape
Statacor Biosciences occupies a minor niche in the mature biotech R&D ecosystem of Rockville, Maryland—a hotspot for pharmaceuticals and life sciences amid trends like personalized medicine and accelerated drug development.[3][4] Its timing post-2008 crisis aligns with biotech's recovery phase, where small firms benefited from government stimuli (e.g., ARRA funding) and rising demand for cost-effective R&D amid patent cliffs for big pharma.[7] Market forces favoring outsourced, lean CRO/biotech services work in its favor, reducing time, cost, and risk for bringing products to market, though its small scale limits ecosystem influence compared to giants like STATCOR Inc. (a separate data-focused CRO).[2][1] It exemplifies persistent micro-players sustaining the innovation pipeline without dominating trends.
Quick Take & Future Outlook
With scant updates since its 2010 founding, Statacor Biosciences appears dormant or highly niche, potentially constrained by limited visibility, funding, or pivots—common for small biotechs in a capital-intensive field.[1][3][8] Upcoming trends like AI-driven drug discovery and biologics could revive it if it adapts, but without product reveals or hiring signals (e.g., via Indeed), stagnation risks persist.[8] Its influence may evolve modestly as a regional R&D enabler, tying back to its crisis-born resilience: survival alone positions it to capitalize on biotech's next wave, though scale-up demands fresh momentum.[7]
